Sitagliptin (phosphate monohydrate)
Key facts
| Invented name |
Tesavel
|
| Active substance |
sitagliptin phosphate monohydrate
|
| Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
| Decision number |
P/0129/2016
|
| PIP number |
Sitagliptin (phosphate monohydrate)
|
| Pharmaceutical form(s) |
Film-coated tablet
|
| Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Merck Sharp and Dohme (Europe), Inc.
|
| Decision type |
PM: decision on the application for modification of an agreed PIP
|